Azora Therapeutics reports Q3 2026 results, reaffirms AT177 IND timeline for first half of 2027
The company said it remains on track to submit an IND and begin a Phase 1a trial for ulcerative colitis candidate AT177 in the first half of 2027.
SEC filing (2)